VIP and neoplasm: Furthermore, VIP antagonist alone or in combination with anti-PD-1 antibody significantly reduced tumor size in CT26 tumor-bearing SCID mice, at least in part, via an increase in M1/M2 macrophage ratio and TAM phagocytic function.